Heart Rate and Cardiovascular Outcomes in Post–Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS Trial
- 10 June 2026
- journal article
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (12) , 1056-1065
Abstract
BACKGROUND: Heart rate (HR) is a key prognostic factor after myocardial infarction (MI), but its relevance in the modern reperfusion era is uncertain. We aim to evaluate the association between HR and β-blocker interruption on cardiovascular outcomes. METHODS: A prespecified secondary analysis of the ABYSS trial (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicted Myocardial Infarction), including 3698 stable post-MI patients (left ventricular ejection fraction ≥40%) randomized to continue or interrupt β-blockers, was conducted. Patients were grouped by prerandomization HR tertiles: P= 0.867). Higher HR was associated with increased risk of death, MI, or stroke (5.5% versus 6.4% versus 9.2%; P 50%). CONCLUSIONS: In stabilized post-MI patients with preserved ejection fraction, higher HR remains associated with adverse cardiovascular events and mortality in the reperfusion era. Interrupting β-blockers substantially increases HR and is consistently linked with worse outcomes irrespective of baseline HR, supporting continuation of β-blocker therapy.Keywords
This publication has 19 references indexed in Scilit:
- Beta-Blockers after Myocardial Infarction without Reduced Ejection FractionNew England Journal of Medicine, 2025
- β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trialsThe Lancet, 2025
- Beta-Blocker Interruption or Continuation after Myocardial InfarctionNew England Journal of Medicine, 2024
- Beta-Blockers after Myocardial Infarction and Preserved Ejection FractionNew England Journal of Medicine, 2024
- βeta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trialAmerican Heart Journal, 2023
- Beta-blocker prescription and outcomes in uncomplicated acute myocardial infarction: Insight from the ePARIS registryArchives of Cardiovascular Diseases, 2022
- Do Patients need Lifelong β-Blockers after an Uncomplicated Myocardial Infarction?American Journal of Cardiovascular Drugs, 2019
- Heart rate is a prognostic risk factor for myocardial infarction: A post hoc analysis in the PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack) study populationInternational Journal of Cardiology, 2013
- First ultra-short-acting beta-adrenergic blocking agent: Its effect on size and segmental wall dynamics of reperfused myocardial infarcts in dogsThe American Journal of Cardiology, 1983
- A Double-Blind Trial of Metoprolol in Acute Myocardial InfarctionNew England Journal of Medicine, 1983